Pfizer, Allergan in deal talks to create drug giant
Pfizer and Botox maker Allergan are discussing a potential deal that could be the biggest of 2015, a year marked by a rapid-fire pace of megadeals, particularly in health care.
in a surge of huge tie-ups across nearly every sector, especially health care.
Analysts speculated that Pfizer would have to pay $390 to $400 per share for Allergan, making the deal worth at least $153 billion. If a merger occurred, the combined company would have a market capitalization in excess of $330 billion, including Allergan's present value of about $113 billion.
